EUCTR2005-005375-15-BE进行中（未招募）不适用
Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation - MCL elderly
GELA0 个研究点目标入组 570 人开始时间: 2006年1月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 570
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with histologically confirmed mantle cell lymphoma
- •- Advanced stages II-IV
- •- Previously untreated
- •- 65 years and older or 60-65 if not eligible for high dose chemotherapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-WHO performance status of 3 or more
- •-Known anti-murine antibody (HAMA) reactivity or Known hypersensitivity to murine antibodies
研究者
相似试验
招募中
3 期
Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone.focal segmental glomerulosclerosisidiopathic nephrotic syndromeminimal change disease10029149NL-OMON44222Radboud Universitair Medisch Centrum40
进行中（未招募）
1 期
Comparison of rituximab with prolonged treatment with prednisone in patients with idiopathic nephrotic syndromeEUCTR2017-003366-27-NLRadboud University Nijmegen Medical Center40
进行中（未招募）
不适用
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
Unknown
3 期
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell LymphomaCD20+ Aggressive Lymphoma, Mantle Cell LymphomaNCT01933711University Hospital Heidelberg328
进行中（未招募）
1 期
Single-agent rituximab as maintenance treatment versus observation after combined induction immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than 65 years with previously untreated B-cell chronic lymphocytic leukemia (B-CLL): a phase III intergroup trial of the GOELAMS and the FCGCLL/WM groups. - LLC 2007 SAEUCTR2007-001015-28-FRCHU TOURS304